Assessing the new and emerging treatments for atopic dermatitis

Lawrence F. Eichenfield; Sheila F. Friedlander; Eric L. Simpson; Alan D. Irvine

doi:10.12788/j.sder.2016.043

Assessing the new and emerging treatments for atopic dermatitis

Lawrence F. Eichenfield, Sheila F. Friedlander, Eric L. Simpson, Alan D. Irvine

Dermatology

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (T_H2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on T_H2 cells (CRT_H2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.

Original language	English (US)
Pages (from-to)	92S-96S
Journal	Seminars in cutaneous medicine and surgery
Volume	35
DOIs	https://doi.org/10.12788/j.sder.2016.043
State	Published - Jun 1 2016

Keywords

Atopic dermatitis
Crisaborole
Dupilumab
Interleukin inhibitors
Petrolatum
Skin barrier

ASJC Scopus subject areas

Surgery
Dermatology

Access to Document

10.12788/j.sder.2016.043

Cite this

@article{dd4a215a30b641eea757e6cf953e8ba0,

title = "Assessing the new and emerging treatments for atopic dermatitis",

abstract = "The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.",

keywords = "Atopic dermatitis, Crisaborole, Dupilumab, Interleukin inhibitors, Petrolatum, Skin barrier",

author = "Eichenfield, {Lawrence F.} and Friedlander, {Sheila F.} and Simpson, {Eric L.} and Irvine, {Alan D.}",

note = "Publisher Copyright: {\textcopyright} 2016 published by Frontline Medical Communications.",

year = "2016",

month = jun,

day = "1",

doi = "10.12788/j.sder.2016.043",

language = "English (US)",

volume = "35",

pages = "92S--96S",

journal = "Seminars in Cutaneous Medicine and Surgery",

issn = "1085-5629",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Assessing the new and emerging treatments for atopic dermatitis

AU - Eichenfield, Lawrence F.

AU - Friedlander, Sheila F.

AU - Simpson, Eric L.

AU - Irvine, Alan D.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.

AB - The newer and emerging treatments for atopic dermatitis (AD) focus on blockade of inflammatory cytokines, especially those that derive from T helper cell type 2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) sensitization. Among the proinflammatory cytokines that have been identified as promising therapeutic targets are chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and several monoclonal antibodies that block key cytokine pathways in the innate immune response. Two agents that have been studied in phase III clinical trials are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and dupilumab, an antibody that inhibits the interleukin-4/IL-13 receptor α chain.

KW - Atopic dermatitis

KW - Crisaborole

KW - Dupilumab

KW - Interleukin inhibitors

KW - Petrolatum

KW - Skin barrier

UR - http://www.scopus.com/inward/record.url?scp=85014728974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014728974&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2016.043

DO - 10.12788/j.sder.2016.043

M3 - Article

C2 - 27525671

AN - SCOPUS:85014728974

VL - 35

SP - 92S-96S

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

ER -

Assessing the new and emerging treatments for atopic dermatitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this